Editas Medicine (0IFK) Ratios
Editas Medicine Ratios
GB:0IFK's free cash flow for Q2 2026 was $-29.67M. For the 2026 fiscal year, GB:0IFK's free cash flow was decreased by $-106.00K and operating cash flow was $-29.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 |
| Quick Ratio | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 |
| Cash Ratio | 3.17 | 1.70 | 1.96 | 2.35 | 4.34 |
| Solvency Ratio | -0.97 | -1.12 | -0.98 | -1.39 | -1.51 |
| Operating Cash Flow Ratio | -3.57 | -2.72 | -2.09 | -2.95 | -3.49 |
| Short-Term Operating Cash Flow Coverage | -14.98 | 0.00 | -11.01 | 0.00 | 0.00 |
| Net Current Asset Value | $ 4.65M | $ 82.00M | $ 190.77M | $ 203.11M | $ 383.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.41 | 0.10 | 0.10 | 0.09 | 0.04 |
| Debt-to-Equity Ratio | 2.81 | 0.26 | 0.14 | 0.12 | 0.05 |
| Debt-to-Capital Ratio | 0.74 | 0.21 | 0.12 | 0.11 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 6.84 | 2.54 | 1.43 | 1.43 | 1.22 |
| Debt Service Coverage Ratio | -8.64 | 0.00 | -13.59 | 0.00 | 0.00 |
| Interest Coverage Ratio | -16.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.36 | 0.00 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.93 | 0.43 | 0.64 | 0.64 | 0.39 |
| Net Debt to EBITDA | 0.47 | 0.41 | 0.46 | 0.44 | 0.94 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | -516.60% | 92.24% | 67.85% | 80.22% |
| EBIT Margin | -379.79% | -739.37% | -216.56% | -1146.26% | -756.13% |
| EBITDA Margin | -366.76% | -721.39% | -208.80% | -1114.11% | -736.35% |
| Operating Profit Margin | -245.15% | -777.22% | -216.56% | -1146.26% | -756.13% |
| Pretax Profit Margin | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% |
| Net Profit Margin | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% |
| Continuous Operations Profit Margin | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 161.13% | 94.40% | 90.57% | 97.56% | 99.67% |
| Return on Assets (ROA) | -85.81% | -69.41% | -30.70% | -42.86% | -28.41% |
| Return on Equity (ROE) | -586.56% | -176.57% | -43.89% | -61.12% | -34.77% |
| Return on Capital Employed (ROCE) | -70.81% | -95.00% | -38.81% | -49.75% | -30.63% |
| Return on Invested Capital (ROIC) | -65.65% | -90.01% | -36.77% | -48.56% | -30.14% |
| Return on Tangible Assets | -85.81% | -69.41% | -30.70% | -42.86% | -28.41% |
| Earnings Yield | -87.98% | -226.73% | -19.91% | -36.19% | -10.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.67 | 1.99 | 7.67 | 3.83 | 95.67 |
| Payables Turnover | 0.00 | 36.27 | 0.73 | 0.67 | 1.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.06 | 0.69 | 1.71 | 0.33 | 0.59 |
| Asset Turnover | 0.22 | 0.09 | 0.16 | 0.04 | 0.04 |
| Working Capital Turnover Ratio | 0.25 | 0.13 | 0.27 | 0.05 | 0.06 |
| Cash Conversion Cycle | 136.70 | 173.67 | -450.13 | -452.55 | -360.97 |
| Days of Sales Outstanding | 136.70 | 183.73 | 47.59 | 95.27 | 3.82 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 10.06 | 497.72 | 547.82 | 364.78 |
| Operating Cycle | 136.70 | 183.73 | 47.59 | 95.27 | 3.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.86 | -2.55 | -1.74 | -2.58 | -2.42 |
| Free Cash Flow Per Share | -1.87 | -2.66 | -1.80 | -2.64 | -2.54 |
| Dividend Paid and CapEx Coverage Ratio | -272.23 | -23.83 | -28.01 | -43.07 | -20.53 |
| Capital Expenditure Coverage Ratio | -272.23 | -23.83 | -28.01 | -43.07 | -20.53 |
| Operating Cash Flow Coverage Ratio | -2.15 | -6.00 | -2.72 | -4.04 | -6.21 |
| Operating Cash Flow to Sales Ratio | -4.08 | -6.51 | -1.69 | -9.00 | -6.41 |
| Free Cash Flow Yield | -91.16% | -209.54% | -17.79% | -29.79% | -9.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.14 | -0.44 | -5.02 | -2.76 | -9.33 |
| Price-to-Sales (P/S) Ratio | 4.49 | 3.24 | 9.85 | 30.90 | 70.28 |
| Price-to-Book (P/B) Ratio | 6.67 | 0.78 | 2.20 | 1.69 | 3.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.10 | -0.48 | -5.62 | -3.36 | -10.45 |
| Price-to-Operating Cash Flow Ratio | -1.10 | -0.50 | -5.82 | -3.43 | -10.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | -0.01 | 0.14 | -0.22 | -0.21 |
| Enterprise Value Multiple | -0.75 | -0.03 | -4.26 | -2.33 | -8.60 |
| Enterprise Value | 111.99M | 8.06M | 694.42M | 511.48M | 1.62B |
| EV to EBITDA | -0.75 | -0.03 | -4.26 | -2.33 | -8.60 |
| EV to Sales | 2.76 | 0.25 | 8.89 | 25.95 | 63.35 |
| EV to Free Cash Flow | -0.68 | -0.04 | -5.07 | -2.82 | -9.42 |
| EV to Operating Cash Flow | -0.68 | -0.04 | -5.25 | -2.88 | -9.88 |
| Tangible Book Value Per Share | 0.31 | 1.63 | 4.60 | 5.25 | 8.19 |
| Shareholders’ Equity Per Share | 0.31 | 1.63 | 4.60 | 5.25 | 8.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.46 | 0.39 | 1.03 | 0.29 | 0.38 |
| Net Income Per Share | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 0.99 | 0.91 | 0.98 | 1.00 |
| Research & Development to Revenue | 2.22 | 6.17 | 2.27 | 8.88 | 5.58 |
| SG&A to Revenue | 1.23 | 2.23 | 0.89 | 3.59 | 2.98 |
| Stock-Based Compensation to Revenue | 0.25 | 0.66 | 0.25 | 1.49 | 1.70 |
| Income Quality | 1.03 | 0.89 | 0.86 | 0.80 | 0.85 |
Currency in USD
